Aligos Therapeutics Shares Surge Ahead of Key Scientific Forums

Shares of Aligos Therapeutics Inc experienced a significant rally on Friday, climbing 6.15% to close at $11.40 after reaching an intraday peak of $11.43. This notable advance appears to reflect mounting investor anticipation for the company’s upcoming presentations at major industry conferences scheduled for the following week.

The absence of immediate news suggests the market activity is a direct response to Aligos’s previously announced participation in two pivotal events. Investor focus is centered on six preclinical presentations slated for the International HBV Meeting in Berlin (September 8-12) and an additional presentation at the H.C. Wainwright Global Investment Conference (September 8-10). Particular interest is being directed toward three presentations concerning the company’s lead candidate, ALG-000184, and a newly developed strategy for treating the hepatitis delta virus.

These forthcoming events are expected to provide crucial updates on the Phase 2 B-SUPREME study program, which commenced dosing in August 2025. The candidate has already demonstrated promising antiviral activity in its Phase 1 data readout.

Should investors sell immediately? Or is it worth buying Aligos Therapeutics Inc?

Beyond its clinical pipeline, Aligos has also fortified its operational foundation. In August 2025, the company appointed Ramón Polo as Head of Global Regulatory Affairs, a move that strengthens its regulatory expertise. From a financial perspective, Aligos reported a second-quarter 2025 EPS of -$1.53 and maintains a solid cash position of $122.9 million, which management estimates provides a sufficient runway through the second half of 2026.

The upcoming week is poised to be a significant test for the biotech firm. The central question for investors is whether the data presentations will meet the heightened expectations. All attention will be on the latest developments in the HBV program and the newly introduced HDV treatment approach. While the technical chart picture suggests a cautiously optimistic short-term outlook following Friday’s jump, the fundamental value of these updates will only become clear in the days ahead.